In addition, studies have also found that obesity was significantly associated with adverse outcomes in women with ER+ tumors, and obesity had an impact on ER- or HER2+ tumors (40, 178). Here, ERBB2 is linked to obesity due to melanocortin 4 receptor deficiency.